News

EAACI 2018 Awards

June 2018

New awards for two studies presented at the Congress of the EAACI 2018 (European Academy of Allergy and Clinical Immunology) (Munich, Germany). Both studies, carried out in the Department of Biochemistry of the Complutense University of Madrid and which have had the participation of INMUNOTEK, have been awarded as the best communications in their respective sessions.
More info

Allergoids coupled to mannan. A review

May 2018

Novel glycoconjugates of allergoids coupled to mannan for a next generation of allergy vaccines. Allergo Journal International publishes a review about the development and main features of these novel vaccines targeting dendritic cells.
More info

Sublingual mannan-allergoid conjugates

February 2018

A new study of allergoids conjugated with mannan has been published in Allergy. In this work, the oral mucosa is experimentally analyzed as a route for the administration of these glycoconjugates. Its lower allergenicity, greater uptake by dendritic cells and immunomodulatory properties makes them good candidates for the development of safer and more effective anti-allergic sublingual vaccines.
More info

Clinical trial with UROMUNE in UK

January 2018

A recent study with UROMUNE (MV140) published in the British Journal of Urology International demonstrates its efficacy in the treatment of recurrent urinary tract infections. This condition has a considerable morbidity worldwide and requires the continued use of antibiotics.
More info

BACTEK-MV130 Mechanisms

October 2017

The European Journal of Immunology has published a study on the immunological mechanisms of MV130 (BACTEK) and its effect on dendritic cells and ability to modulate the immune response. BACTEK-MV130 is a bacterial mucosal vaccine that is administered in spray (under the tongue) for the treatment of recurrent respiratory infections in adults and children.
More info

EAACI 2017 Award

June 2017

The study presented at the EAACI 2017 (European Academy of Allergy and Clinical Immunology) (Helsinki, Finland) by Cristina Benito Villalvilla
More info

Immunotherapy Seminars

June 2017

On June 2, has been started the Seminars on allergen-specific immunotherapy: From Leonard Noon to the new vaccines targeted to dendritic cells
More info

FEBS-MPST 2017 Award

May 2017

The study presented by Dr. Ioanna Kalograiaki during the advanced course of the FEBS (Federation of European Biochemical Societies) Matrix Pathology, Signaling and Molecular Targets, has been awarded the best presentation
More info

Madrid Capital of Progress

May 2017

As INMUNOTEK has been included in the FT 1000 ranking of the Financial Times, our CEO, Dr. José Luis Subiza has been interviewed for a special monograph "Madrid Capital del Progreso" of the newspaper El Mundo, where he reviews the present, projects and challenges of the company
More info

South Korean delegation visits INMUNOTEK

May 2017

On May 29, INMUNOTEK was visited by a South Korean delegation from the Gangneung Science and Industry Promotion Agency (GSIPA).
More info